Here’s what we covered:
- [00:00] Introduction and overview of the event
- [02:26] Introduction of the categories: TechTalk, OB City, 3…2…ONE!, Diabetes Grab Bag, and Jeremy Pet Us or Don’t Pet Us
- [04:07] Tech Talk: Abbott’s continuous ketone monitor measuring beta-hydroxybutyrate
- [06:23] Diabetes Grab Bag: Vertex’s lab-grown islet cells eliminating severe hypoglycemia
- [09:51] 3…2…ONE!: Inhaled insulin (Afrezza) approval for adolescents and teens
- [12:01] Tech Talk: The upcoming Dexcom G8 CGM features and naming strategy
- [15:24] OB City: Tirzepatide (Zepbound) and its new indication for sleep apnea
- [19:08] 3…2…ONE!: Tzield (teplizumab) for delaying stage 3 Type 1 Diabetes in kids as young as 1 year old
- [22:15] Diabetes Grab Bag: The frustration of prior authorizations
- [27:02] Jeremy Pet Us or Don’t Pet Us: Hippopotamus
- [28:32] Diabetes Grab Bag: The Eversense 365, Libre 3 Plus, and the new Twiist insulin pump
- [37:05] Jeremy Pet Us or Don’t Pet Us: Manta Ray
- [38:29] OB City: Ozempic side effects and its internet fame
- [42:17] Newsy News Segment: The discrepancy between GLP-1 approvals for Type 1 vs. Type 2 Diabetes
- [51:42] Closing remarks
EVENT INSTRUCTIONS
Please type your questions into the chat box. Include your first name, where you live, how many years you have had diabetes, and/or if you are a healthcare professional. Drs. E and P will attempt to answer as many questions as they can in the time permitted.
